+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Comparison of Parenteral Opioid Dosing in Adult Sickle Cell Disease Patients With Vaso-occlusive Crisis



Comparison of Parenteral Opioid Dosing in Adult Sickle Cell Disease Patients With Vaso-occlusive Crisis



Journal of Pain and Palliative Care PharmacoTherapy 2019: 1-7



Sickle cell disease (SCD) is a chronic condition characterized by multiple vaso-occlusive complications, including acute pain crisis. The mainstay of treatment for patients presenting with vaso-occlusive crisis (VOC) is pain control and adequate hydration. Currently, there are no studies to determine an optimal pain control regimen in adult SCD patients. The main objective of this study is to evaluate whether outcomes differ in patients with VOC based on pain management treatment modality. A retrospective review of admissions with a primary diagnosis of VOC admitted to our facility was conducted. The primary outcome was to compare the average length of stay (LOS) in patients treated with intermittent injection (INT) or patient-controlled analgesia (PCA). Secondary outcomes assessed included 30-day readmission, treatment failure, and impact on pain scores. Of 302 admissions screened, 150 met inclusion criteria (INT: n = 100; PCA: n = 50). Selection of initial pain control regimen showed no difference in average LOS (INT: 5.96 ± 4.19 days vs. PCA: 6.01 ± 3.47 days; P = .94) or 30-day readmission rates (INT: 21% vs. PCA: 16%; P = .52). Treatment failure was significantly higher in the INT group, occurring in 64% of patients vs. 14% in the PCA group (P < .0001). Pain scores were not significantly impacted by selection of pain regimen. Our study indicates that INT and PCA treatment modalities are both effective at controlling pain in VOC; however, more patients in the INT group were characterized as having a treatment failure. Based on our results, it is reasonable to initiate PCA as the primary pain treatment strategy in SCD patients presenting in VOC.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 066611775

Download citation: RISBibTeXText

PMID: 30896312

DOI: 10.1080/15360288.2019.1577938


Related references

Assessment of patient-controlled analgesia versus intermittent opioid therapy to manage sickle-cell disease vaso-occlusive crisis in adult patients. Saudi Journal of Anaesthesia 11(4): 437-441, 2017

Adult patients with sickle cell disease report more negative hospital experiences during vaso-occlusive crisis than a national sample of U.S. adults. Journal of General Internal Medicine 23(Suppl. 2): 244, 2008

Assessment of ketoprofen for acute vaso-occlusive crisis in adult patients with sickle cell disease A randomized double blind monocentric Study. Blood 102(11): 765a, November 16, 2003

Acute vaso-occlusive crisis in patients with sickle cell disease. Nursing 47(1): 67-68, 2017

Heart rate variability study in adult Nigerian subjects with sickle cell disease during vaso-occlusive crisis. Nigerian Postgraduate Medical Journal 26(1): 8-12, 2019

Tramadol use in pediatric sickle cell disease patients with vaso-occlusive crisis. World Journal of Clinical Pediatrics 2(4): 65-69, 2014

Vaso-occlusive crisis-associated neutrophil dysfunction in patients with sickle-cell disease. American Journal of the Medical Sciences 294(4): 253-257, 1987

IL-8 levels in sickle cell disease Brazilian patients in vaso-occlusive crisis. Blood 96(11 Part 2): 16b-17b, November 16, 2000

An innovative short-stay health care model for treatment of uncomplicated vaso-occlusive crisis in adult sickle cell disease patients in Canada to reduce emergency department utilization. Cjem 2017: 1-8, 2017

Use of laboratory data in patients with sickle cell disease vaso-occlusive pain crisis. Journal of Investigative Medicine 45(1): 33A, 1997

The role of infection in the pathogenesis of vaso-occlusive crisis in patients with sickle cell disease. Mediterranean Journal of Hematology and Infectious Diseases 3(1): E2011028, 2011

Anti-annexin V IgG and IgM antibodies in sickle cell disease patients with vaso-occlusive crisis. Annals of Hematology 90(9): 1031-1036, 2011

Protein Z polymorphisms associated with vaso-occlusive crisis in young sickle cell disease patients. Annals of Hematology 91(8): 1215-1220, 2012

The value of ultrasound and aspiration in differentiating vaso-occlusive crisis and osteomyelitis in sickle cell disease patients. Clinical Radiology 54(10): 636-639, 1999

Pattern of serum cytokine expression and T-cell subsets in sickle cell disease patients in vaso-occlusive crisis. Clinical and Vaccine Immunology 17(4): 602-608, 2010